Results 151 to 160 of about 939 (187)
Ubrogepant for the Treatment of Migraine
Expert Opinion on Pharmacotherapy, 2020 Migraine is a neurovascular disorder involving neurogenic inflammation and transmission of trigeminovascular nociceptive pathways mediated by Calcitonin Gene-Related Peptide (CGRP). Several small molecules antagonizing the CGRP receptor have been developed as migraine-specific acute medications. The CGRP receptor antagonist ubrogepant, also known as MK-
Luana Lionetto +2 more
exaly +4 more sources
Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies
International Journal of Neuroscience, 2022 Introduction: The efficacy of ubrogepant 50 mg versus 100 mg daily for migraine remained controversial. We conducted a systematic review and meta-analysis to compare the efficacy and safety of ubrogepant 50 mg versus 100 mg daily on treatment in migraine patients.Methods: We have searched PubMed, EMbase, Web of science, EBSCO, Cochrane library ...
Shu-Zhi, Wu, Linglong, Chen
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Real-World Efficacy, Tolerability, and Safety of Ubrogepant
Headache, 2021Abstract Objective To assess the real‐world efficacy, tolerability, and safety of ubrogepant in a tertiary headache center. Background The efficacy and safety of ubrogepant for the acute treatment of migraine were ...
Chia-Chun Chiang +2 more
exaly +3 more sources
Treating acute migraine with ubrogepant
JAAPA, 2023ABSTRACT Acute migraine affects millions of people and is one of the most common primary care complaints in the United States. Available first-line abortive treatments are limited and vary in efficacy. Newer medications such as calcitonin gene-related peptide (CGRP) receptor antagonists may be a useful alternative.
openaire +2 more sources
Drugs of Today, 2020
Migraine is the primary headache disorder affecting a significant population worldwide. Ubrogepant is an orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adults.
openaire +2 more sources
Migraine is the primary headache disorder affecting a significant population worldwide. Ubrogepant is an orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adults.
openaire +2 more sources
Ubrogepant-Einsatz schon bei mildem Migräne- Schmerz?
Fortschritte der Neurologie · Psychiatrie, 2023Leichte Kopfschmerzen zu Beginn einer Migräneattacken verstärken sich häufig und rasch. Bei der Akutbehandlung sehen regulatorische Behörden eine Therapie erst ab moderater oder hoher Schmerzintensität vor, während Leitlinien den Therapiebeginn bei einer ...
openaire +1 more source
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Ubrelvy be reimbursed by public drug plans for the acute treatment of migraine, with or without aura, in adults if certain conditions are met. The Canadian Drug Expert Committee (CDEC) determined that Ubrelvy demonstrates acceptable clinical value compared with appropriate comparators (triptans) in adult ...
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Ubrelvy be reimbursed by public drug plans for the acute treatment of migraine, with or without aura, in adults if certain conditions are met. The Canadian Drug Expert Committee (CDEC) determined that Ubrelvy demonstrates acceptable clinical value compared with appropriate comparators (triptans) in adult ...
openaire +1 more source